Sanofi (EPA:SAN) Given a €105.00 Price Target at Credit Suisse Group

Credit Suisse Group set a €105.00 ($117.98) price objective on Sanofi (EPA:SAN) in a research note published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

SAN has been the subject of a number of other reports. Kepler Capital Markets set a €99.00 ($111.24) price target on Sanofi and gave the company a buy rating in a research note on Wednesday. Goldman Sachs Group set a €105.00 ($117.98) price target on Sanofi and gave the company a buy rating in a research note on Wednesday. Deutsche Bank set a €99.00 ($111.24) price target on Sanofi and gave the company a buy rating in a research note on Tuesday, April 14th. JPMorgan Chase & Co. set a €103.00 ($115.73) price target on Sanofi and gave the company a buy rating in a research note on Thursday, July 9th. Finally, UBS Group set a €101.00 ($113.48) price target on Sanofi and gave the company a buy rating in a research note on Thursday, June 25th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of €101.54 ($114.09).

Shares of SAN stock opened at €88.55 ($99.49) on Thursday. Sanofi has a 12-month low of €63.09 ($70.89) and a 12-month high of €92.97 ($104.46). The business has a 50 day simple moving average of €91.31 and a 200 day simple moving average of €87.93.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: What is included in the gross domestic product?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.